EverZom
French tech company | Builders Republic
About
Clinical-stage biotech developing regenerative therapies based on exosomes — tiny cell-derived vesicles that repair and calm damaged tissue — paired with its EVerGel hydrogel for sustained local delivery, with a lead program targeting Crohn's-related anal fistulas plus a proprietary bioproduction platform for industrial-scale exosome manufacturing.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2019
- City
- STRASBOURG
- Region
- IDF
- Tracked rounds
- 2
- Amount raised
- 11 M€ raised since 2020
Funding rounds
- Series A — 2025
- Seed — 2020